-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Generations change, new and old emerge one after another
.
On February 12, 2022, the State Food and Drug Administration announced that Pfizer's new coronavirus treatment drug nematevir tablet/ritonavir tablet combination package import registration has been approved with emergency conditions
.
▲ Source: State Food and Drug Administration official website
As a small-molecule oral drug, the drug is registered for the treatment of adults with mild to moderate COVID-19 patients with high risk factors for progression to severe disease, such as the elderly, patients with chronic kidney disease, diabetes, cardiovascular disease, and chronic lung disease
.
This may be complementary to some domestic drugs, and given the current degree of virus mutation, any drug may face the same outcome, and it is difficult to work alone
.
In the process of medication, the virus will develop drug resistance, just like HIV, which requires a cocktail therapy; Helicobacter pylori requires a quadruple therapy
They all use drugs to inhibit microorganisms at different stages, and strangle them layer by layer
.
Some drugs may be concentration-dependent, while others may be time-dependent.
This strategy benefits 105 low- and middle-income countries compared to Merck's approval of many Chinese pharmaceutical companies to produce the COVID-19 antiviral drug Molnupiravir
.
Pfizer has a similar policy for the drug, with a licensing agreement with the Medicines Patent Pool (MMP) covering 95 low- and middle-income countries
Generally, such drugs are relatively expensive, so using the partial opening model can expand the scope of benefits and reduce the risk of the spread of the epidemic
.
For the domestic prevention and control situation, reducing the social cost of epidemic prevention as soon as possible is the top priority
However, this drug is not used for pre-exposure or post-exposure prophylaxis, so it is not a substitute for vaccines, and the use of drugs will not affect the normal use of vaccines
.
Whether a drug is effective is one thing, and whether there are more serious adverse reactions is also related to the promotion and use of the drug
.
Impaired taste, diarrhea, etc.
Of course, the existing domestic new crown drugs have been well promoted by the media in the early stage
.
However, as the epidemic spreads and continues, it often falls into silence
According to past experience, if the vaccine can be properly prevented, the pressure of treatment and medication will be reduced a lot, because the number of diseases can be limited
.
However, when the vaccine has limited efficacy, especially when the virus mutates frequently, more requirements must be placed on the therapeutic drug
It is not clear how Pfizer's production capacity of the drug will be able to meet the volume requirements
.
If it is effective, it is best to build a factory in China and adopt the mode of cooperation.
